Prostate Cancer Prevention by Procyanidins in Grape Seed Extract

葡萄籽提取物中的原花青素预防前列腺癌

基本信息

  • 批准号:
    8309786
  • 负责人:
  • 金额:
    $ 32.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-02-14 至 2015-05-31
  • 项目状态:
    已结题

项目摘要

6. PROJECT SUMMARY ABSTRACT Prostate cancer (PCA) is the most frequently diagnosed malignancy in elderly men, and is rated as second leading cause of cancer deaths in men. The malignancy has long latent period of development from pre-neoplastic lesion to full-blown cancer providing ample time to intervene or alter the progression of this disease employing chemopreventive strategies. Additionally, numerous studies have shown that the risk for certain cancers could be lowered by dietary manipulations, especially by increased consumption of fruits and vegetables. Accordingly, there has been serious interest in identifying diets or dietary constituents (both nutritive and non-nutritive phytochemicals) for their potential use as chemopreventive agents. Grape seed extract (GSE), a rich and commercially available source of proanthocyanidins (also known as procyanidins), is usually consumed as a health supplement for its wide range of beneficial effects. Regarding cancer, several studies by us and others have demonstrated the anti-cancer and chemopreventive efficacy of GSE against various epithelial malignancies including PCA cells. Since GSE represents a complex mixture of polyphenols, the central focus of the studies during the last funding period was to isolate and characterize active component(s) in GSE to carry out detailed mechanistic and efficacy studies for anticancer activity employing pure and defined agents. We recently isolated and characterized procyanidin B2- 3,3'-di-O-gallate (B2-G2) as an active compound from GSE with strong anti-cancer activity against human prostate carcinoma DU145 cells. Further studies with this compound revealed that it is taken up by PCA cells and that it causes both cytotoxic as well as cell growth inhibitory effects. Additional studies revealed that B2-G2 causes both cell cycle arrest and apoptosis induction in human PCA cells carrying functional androgen receptor; these cells specifically represent majority of human prostate tumors. Importantly, B2-G2 did not show cytotoxicity in normal human prostate epithelial and stromal cells, showing its selectivity in human PCA cells. Since uncontrolled proliferation due to deregulated cell cycle progression and loss of apoptotic function are the major underlying defects in most of the cancers including PCA and since B2-G2 exerts strong cell cycle arrest and apoptotic responses in PCA cells, our central hypothesis is that procyanidin B2-3,3'-di-O-gallate selectively induces cell cycle arrest and apoptosis in neoplastic prostate epithelial cells which collectively leads to its preventive and therapeutic efficacy against PCA. Our specific aims are to: 1) prepare B2-G2 needed for planned mechanistic, bioavailability and efficacy studies, 2) conduct in vitro studies to address mechanism of action of B2-G2 involved in cell cycle arrest and apoptosis, and 3) determine efficacy and bioavailability of B2-G2 employing an in vivo transgenic carcinoma of the mouse prostate (TRAMP) model, which closely and naturally mimics the progression of prostatic carcinoma in humans. Overall, our long term goal is to develop procyanidin B2-3,3'-di- O-gallate as a mechanism-based potential chemopreventive agent against PCA. 7. PROJECT NARRATIVE Prostate cancer is second leading cause of cancer-related deaths in United States, and thus is an important public health issue. Use of chemopreventive agents seems to be more effective approach for the control of prostate cancer as it has long latent period of development; sometimes over decade from precursor lesions to full blown disease. Current grant proposal focuses on the development of one such agent, which has been isolated from grape seed extract, a widely consumed health supplement. Outcomes of our proposed research will provide a mechanism-based agent for the prevention of prostate cancer in humans.
6。项目摘要摘要 前列腺癌(PCA)是老年男性最常见的恶性肿瘤,被评为第二大领先 男性癌症死亡的原因。恶性肿瘤具有长期的潜在发展时期,从神经前病变到 成熟的癌症提供了充足的时间进行干预或改变这种疾病的进展 化学预防策略。此外,许多研究表明,某些癌症的风险可能是 降低了饮食操纵,特别是通过增加水果和蔬菜的消耗。因此,那里 人们对识别饮食或饮食成分(营养和非营养植物化学物质)非常感兴趣 因为它们的潜在用作化学预防剂。葡萄种子提取物(GSE),富裕且可商用的 普罗氏蛋白酶(也称为procyanidins)的来源通常被作为其广泛的健康补充剂食用 一系列有益效果。关于癌症,我们和其他研究证明了抗癌者 GSE对包括PCA细胞在内的各种上皮恶性肿瘤的化学预防疗效。自gse以来 代表多酚的复杂混合物,在最后一个资金期间研究的中心重点是 分离和表征GSE中的活动成分,以进行详细的机械和功效研究 抗癌活性采用纯和定义的药物。我们最近分离并表征了procyanidin b2- 3,3'-di-o-gallate(B2-g2)作为GSE的活性化合物,具有强大的抗癌活性对人前列腺 DU145细胞癌。该化合物的进一步研究表明,它被PCA细胞占用,并且 引起细胞毒性和细胞生长抑制作用。其他研究表明,B2-G2引起了两者 携带功能性雄激素受体的人PCA细胞中细胞周期停滞和凋亡诱导;这些细胞 特别代表大多数人前列腺肿瘤。重要的是,B2-G2在正常情况下未显示细胞毒性 人前列腺上皮细胞和基质细胞,显示其在人PCA细胞中的选择性。自从不受控制 由于失调的细胞周期进程和凋亡功能的丧失而引起的增殖是主要的基础 包括PCA在内的大多数癌症和B2-G2施加强大的细胞周期停滞和凋亡的缺陷 PCA细胞的反应,我们的中心假设是procyanidin b2-3,3'-di-o-gallate选择性诱导细胞 肿瘤前列腺上皮细胞中的循环停滞和凋亡,该细胞共同导致其预防 和针对PCA的治疗功效。我们的具体目的是:1)准备计划中所需的B2-G2 机械,生物利用度和功效研究,2)在体外研究中进行B2-G2的作用机理 参与细胞周期停滞和凋亡,3)确定B2-G2的功效和生物利用度 小鼠前列腺(Tramp)模型的体内转基因癌,它们紧密而自然地模仿 人类前列腺癌的进展。总体而言,我们的长期目标是开发procyanidin b2-3,3'-di- O-Gallate是针对PCA的基于机制的潜在化学预防剂。 7。项目叙述 前列腺癌是美国与癌症相关死亡的第二大原因,因此是一个重要的 公共卫生问题。化学预防剂的使用似乎是控制的更有效方法 前列腺癌长期以来一直具有潜在的发展时期;有时从前体病变到十多年 完全吹牛的疾病。当前的赠款提案着重于一个这样的代理人的发展 从葡萄种子提取物中分离出来,这是一种广泛消费的健康补充剂。我们提议的研究的结果 将为预防人类前列腺癌提供基于机制的药物。

项目成果

期刊论文数量(21)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Role of oxidative stress in cytotoxicity of grape seed extract in human bladder cancer cells.
  • DOI:
    10.1016/j.fct.2013.06.039
  • 发表时间:
    2013-11
  • 期刊:
  • 影响因子:
    4.3
  • 作者:
    Raina, Komal;Tyagi, Alpna;Kumar, Dileep;Agarwal, Rajesh;Agarwal, Chapla
  • 通讯作者:
    Agarwal, Chapla
A novel anticancer agent, decursin, induces G1 arrest and apoptosis in human prostate carcinoma cells.
  • DOI:
    10.1158/0008-5472.1035.65.3
  • 发表时间:
    2005-02
  • 期刊:
  • 影响因子:
    11.2
  • 作者:
    Dongsool Yim;R. Singh;C. Agarwal;S. Lee;Hyungjoon Chi;R. Agarwal
  • 通讯作者:
    Dongsool Yim;R. Singh;C. Agarwal;S. Lee;Hyungjoon Chi;R. Agarwal
Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-kappaB: implications for angioprevention and antiangiogenic therapy.
水飞蓟宾通过细胞周期停滞和下调生存素、Akt 和 NF-κB 强烈抑制人内皮细胞的生长和存活:对血管预防和抗血管生成治疗的影响。
  • DOI:
    10.1038/sj.onc.1208276
  • 发表时间:
    2005
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Singh,RanaP;Dhanalakshmi,Sivanandhan;Agarwal,Chapla;Agarwal,Rajesh
  • 通讯作者:
    Agarwal,Rajesh
Gallic acid, an active constituent of grape seed extract, exhibits anti-proliferative, pro-apoptotic and anti-tumorigenic effects against prostate carcinoma xenograft growth in nude mice.
  • DOI:
    10.1007/s11095-009-9926-y
  • 发表时间:
    2009-09
  • 期刊:
  • 影响因子:
    3.7
  • 作者:
    Kaur, Manjinder;Velmurugan, Balaiya;Rajamanickam, Subapriya;Agarwal, Rajesh;Agarwal, Chapla
  • 通讯作者:
    Agarwal, Chapla
Differential effect of grape seed extract against human non-small-cell lung cancer cells: the role of reactive oxygen species and apoptosis induction.
  • DOI:
    10.1080/01635581.2013.785003
  • 发表时间:
    2013
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Tyagi A;Raina K;Gangar S;Kaur M;Agarwal R;Agarwal C
  • 通讯作者:
    Agarwal C
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CHAPLA AGARWAL其他文献

CHAPLA AGARWAL的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CHAPLA AGARWAL', 18)}}的其他基金

Colon Cancer Chemoprevention by Grape Seed Extract
葡萄籽提取物化学预防结肠癌
  • 批准号:
    7599606
  • 财政年份:
    2007
  • 资助金额:
    $ 32.25万
  • 项目类别:
Colon Cancer Chemoprevention by Grape Seed Extract
葡萄籽提取物化学预防结肠癌
  • 批准号:
    7416658
  • 财政年份:
    2007
  • 资助金额:
    $ 32.25万
  • 项目类别:
Colon Cancer Chemoprevention by Grape Seed Extract
葡萄籽提取物化学预防结肠癌
  • 批准号:
    7809455
  • 财政年份:
    2007
  • 资助金额:
    $ 32.25万
  • 项目类别:
Colon Cancer Chemoprevention by Grape Seed Extract
葡萄籽提取物化学预防结肠癌
  • 批准号:
    7259998
  • 财政年份:
    2007
  • 资助金额:
    $ 32.25万
  • 项目类别:
Colon Cancer Chemoprevention by Grape Seed Extract
葡萄籽提取物化学预防结肠癌
  • 批准号:
    8056607
  • 财政年份:
    2007
  • 资助金额:
    $ 32.25万
  • 项目类别:
Prostate Cancer Prevention by Procyanidins in Grape Seed Extract
葡萄籽提取物中的原花青素预防前列腺癌
  • 批准号:
    7643461
  • 财政年份:
    2003
  • 资助金额:
    $ 32.25万
  • 项目类别:
Prostate Cancer Prevention by Procyanidins in Grape Seed Extract
葡萄籽提取物中的原花青素预防前列腺癌
  • 批准号:
    7526497
  • 财政年份:
    2003
  • 资助金额:
    $ 32.25万
  • 项目类别:
Prostate Cancer Prevention by Procyanidins in Grape Seed Extract
葡萄籽提取物中的原花青素预防前列腺癌
  • 批准号:
    8079119
  • 财政年份:
    2003
  • 资助金额:
    $ 32.25万
  • 项目类别:
Prostate Cancer Prevention by Procyanidins in Grape Seed
葡萄籽中的原花青素预防前列腺癌
  • 批准号:
    7174782
  • 财政年份:
    2003
  • 资助金额:
    $ 32.25万
  • 项目类别:
Prostate Cancer Prevention by Procyanidins in Grape Seed Extract
葡萄籽提取物中的原花青素预防前列腺癌
  • 批准号:
    7860699
  • 财政年份:
    2003
  • 资助金额:
    $ 32.25万
  • 项目类别:

相似国自然基金

靶向Sub-LBP的新型雄激素受体拮抗剂的发现及其抗前列腺癌活性研究
  • 批准号:
    82304381
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
FMNL2介导的雄激素受体磷酸化促进前列腺癌恩扎卢胺耐药的作用及机制研究
  • 批准号:
    82303885
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
HJURP调控PRDX1增加雄激素受体蛋白稳定性导致前列腺癌细胞对恩扎卢胺耐药的机制
  • 批准号:
    82373188
  • 批准年份:
    2023
  • 资助金额:
    48 万元
  • 项目类别:
    面上项目
KMT5A/YAP/FASN轴介导管腔雄激素受体型三阴性乳腺癌抗雄治疗耐药的分子机制研究
  • 批准号:
    82373359
  • 批准年份:
    2023
  • 资助金额:
    48 万元
  • 项目类别:
    面上项目
PAK1介导前列腺癌抗雄激素受体治疗交叉耐药的机制研究
  • 批准号:
    82373362
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目

相似海外基金

"DNMT and TET1 reprogramming as a targetable mechanism of resistance in advanced prostate cancer"
“DNMT 和 TET1 重编程作为晚期前列腺癌的靶向耐药机制”
  • 批准号:
    10681632
  • 财政年份:
    2023
  • 资助金额:
    $ 32.25万
  • 项目类别:
Neuroendocrine differentiation post anti-androgenic therapy: Role of Tribbles 2
抗雄激素治疗后的神经内分泌分化:Tribbles 2 的作用
  • 批准号:
    10659525
  • 财政年份:
    2023
  • 资助金额:
    $ 32.25万
  • 项目类别:
Evaluating prostate cancer phenotype and genotype classification from circulating tumor DNA as biomarkers for predicting treatment outcomes
根据循环肿瘤 DNA 评估前列腺癌表型和基因型分类作为预测治疗结果的生物标志物
  • 批准号:
    10804464
  • 财政年份:
    2023
  • 资助金额:
    $ 32.25万
  • 项目类别:
Mechanisms and vulnerabilities of ERG-driven luminal fate in prostate cancer
前列腺癌中 ERG 驱动的管腔命运的机制和脆弱性
  • 批准号:
    10572836
  • 财政年份:
    2023
  • 资助金额:
    $ 32.25万
  • 项目类别:
Targeting Vulnerabilities Exposed by Cancer Treatment-Induced Lineage Plasticity
针对癌症治疗引起的谱系可塑性暴露的脆弱性
  • 批准号:
    10650286
  • 财政年份:
    2022
  • 资助金额:
    $ 32.25万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了